Bio — Scientific Advisory Board member

James A. Neubrander, M.D.

Dr. Neubrander received his M.D. degree from Loma Linda University in 1975, after which he completed his residency in pathology at the University of South Florida. Currently he is in private practice in New Jersey where he dedicates the majority of his time treating children with autism, ADD, ADHD, and other neurodevelopmental and learning disorders. He travels extensively speaking at national and international conferences and symposiums due to his expertise in effectively helping these children with new treatments or modifications of established protocols in order to enhance clinical outcomes beyond the results that are classically reported by parents, teachers, and therapists.

Dr. Neubrander is known as “The Father of Methyl-B12” In 2002, his career changed dramatically after he accidentally discovered the incredible power that the methyl form of the common B12 vitamin exhibits in children with autism and other neurodevelopmental disorders by eliciting significantly increased executive function, speech and language, as well as socialization and emotion. Since that point in time, a large percentage of his research efforts have been directed at perfecting various protocols in order to improve the delivery and effectiveness of this therapy. The impact of his discovery of methylcobalamin is currently being realized worldwide by tens of thousands of children and adults, not only for neurodevelopmental disorders, but also for numerous acute and chronic diseases that affect the brain, either directly or indirectly.

In addition to his work with methylcobalamin, Dr. Neubrander has pioneered the use of hyperbaric oxygen for children on the autistic spectrum. While his protocols have incorporated the standard principles of hyperbaric therapy that have been used for years, he has expanded them to include other mechanisms of action previously unknown or little discussed. By using advanced hyperbaric treatment protocols, he has been able to very quickly produce speech in many children who previously had minimal to no language, to increase socialization that at times approaches that seen in neurotypical children, to augment awareness by twofold or more, and have children not infrequently lose their diagnosis and become virtually indistinguishable from their peers.

The goal of his life's work is to combine evidence-based medicine with innovative treatments that integrate the best of all worlds for the common goal he believes we all share, that is, to treat each patient as an individual in order to find the most effective and safe treatments to help those patients today.

Back to Board Of Directors & Scientific Advisory Board page